[Translation]

June 12, 2023

To Shareholders,

Company Name: Renascience Inc.
Representative: Koji Naito, President & CEO
(Code: 4889 TSE Growth)
Inquiries: Department of Administration

Announcement of Conclusion of Collaboration Agreement with NEC Corporation (NEC)

The Company is pleased to announce that the Company has decided to enter into a collaboration agreement ("Agreement") on medical applications of artificial intelligence (AI) with NEC Corporation ("NEC").

Although this matter does not fall under the category of timely disclosure as stipulated by the rules of the Tokyo Stock Exchange, the Company voluntarily discloses this information because the Company believes it is useful for the Shareholders.

1. Background of the Agreement

The Company conducts research and development of various modalities (pharmaceuticals, medical devices, and other forms of treatment) to solve medical issues, and one of these is the development of software as a medical device (SaMD) that utilize AI. The Company has already started projects in medical fields such as diabetes, hemodialysis, respiratory diseases, and dysphagia, and plans to further expand the projects to different medical departments and diseases in the future. In January 2022, the Company established "TREx" as an open innovation research center within Tohoku University Graduate School of Medicine. To accelerate research and development of medical solutions using cutting-edge AI technology, the Company has decided to execute the Agreement with NEC, one of the leading companies in AI. The Company will promote the development of various SaMD for diagnosis and treatment in collaboration with Tohoku University, NEC Solution Innovator, Ltd. ("NES") and NEC.

2. Details of the Agreement

In this collaboration, the Company will utilize "TREx," an open innovation research center, established within Tohoku University Graduate School of Medicine to develop various SaMD using the multiple AIs (algorithms) that the Company licensed from NEC, by making the AIs learn medical data that the Company have acquired from various medical institutions and departments, and by cultomizing the AI engines for medical use according to the advice of experienced physicians, and will develop various SaMD using the AIs that support physicians in diagnosis and treatment. The developed SaMD will be put to practical use by demonstrating them in clinical studies at medical institutions. With regard to the SaMD for supporting diabetes treatment (prediction of insulin dosage) and the SaMD for supporting maintenance hemodialysis treatment (prediction of total water withdrawal and blood pressure decrease), the Company plans to conduct clinical performance tests as the verification tests for filing of the regulatory approval in the next fiscal year in collaboration with several medical institutions, with funding from the Japan Agency for

Medical Research and Development (AMED).

3. Outlook for the future

This matter will have no impact on the business performance of the Company.

End

Reference: Q&A regarding the execution of this Agreement

Q1: How is this different from the disclosure on November 30, 2022?
A1: The disclosure on November 30, 2022, was the conclusion of a collaboration agreement with NES. The current disclosure is the conclusion of the Agreement with NEC, the parent company of NES. The purpose of our research with NEC or NES is different. (See Q2)

Q2: What is the difference between the NEC and NES collaborations?
A2: The Company works on the development of software as a medical device (SaMD) using AI, and have started projects in medical fields such as diabetes, hemodialysis, respiratory diseases, and dysphagia. The Company develops the core AI with NEC, and develops the overall system (cloud environment, user interface, etc.) to operate this AI in medical institutions with NES.

Q3: What are the specifics of your collaboration with NEC?
A3: The most appropriate type of AI engine should be selected based on the targeted medical issue and the type of relevant medical data. Instead of looking for a medical field where a specific AI engine can be utilized, it is necessary to "select the best AI engine (in some cases, develop our own)" to solve a specific medical problem, and furthermore, to customize the AI engine with medical data and physicians' advice in the medical field. NEC has a wide variety of basic AI engines, and the Company has licensed multiple AI engines from NEC. In "TREx," an open innovation research center established within Tohoku University Graduate School of Medicine in January 2022, the Company will develop the core AIs for various SaMD by making the AI engines learn medical data acquired by the Company from various medical institutions and departments, and by customizing the AIs for medical use with the advice of experienced physicians.

Q4: How will this Agreement affect the research and business of the Company?
A4: The application of AI to the medical field is an important theme with great potential, but the stakeholders who play significant roles in the research and development are facing individual challenges. Physicians (medical institutions) are well versed in medical issues and have abundant medical data, but they have little AI technologies and networks with AI vendors, making them difficult launch specific research and development projects by themselves. On the other hand, IT vendors with AI technologies are interested in applying the technologies to the growing medical field, but practical application is not easy because they have little access to medical needs and medical data due to their limited network with physicians (medical institutions), and they hardly have experience in pharmaceutical administration and regulations, including the Pharmaceutical and Medical Device Act. In addition, it is often difficult for pharmaceutical and healthtech companies, at the exit of the R&D, that wish to commercialize

medical applications of AI to handle everything from research to business development on their own, both in terms of time and resources. Therefore, it is important to establish a framework in which physicians (medical institutions) with issues, IT vendors with AI technology, and exit companies (pharmaceutical and health tech companies) collaborate from the outset to promote the development.

The Company leverages its own unique characteristics, such as the ability to obtain medical issues and medical data from the network of numerous medical institutions and multiple medical departments, the experience in pharmaceutical administrations and regulatiions gained in the process of conducting investigator-initiated clinical trials for pharmaceutical products, and collaborative relationship with IT vendors with AI technologies and pharmaceutical and health tech companies at the exit to develop various programs. This Agreement will enable us to conduct research and develop business on SaMD for many medical issues, and together with the collaboration agreement with NES signed on November 30, 2022, we can accelerate the development of systems to run the developed AI in the medical field.

Q5: What pipelines are in development in the SaMD research?

A5: The SaMD for supporting diabetes treatment was selected for the AMED "Innovation in Medical Engineering (Development and Commercialization Poject)" in FY2022, and the Company plans to conduct the clinical performance test from FY2023 as the verification test for application for regulatory approval. The SaMD for supporting maintenance hemodialysis was also selected for the AMED "Research on Development of New Medical Devices" in FY2023 and is scheduled to start the clinical performance test within two years. The SaMD for respiratory function diagnosis is scheduled to complete research and development phase with Kyoto University and CHEST MI Inc in May 2023 as planned, after which the research for the practical application will be conducted by CHEST MI Inc. The SaMD for diagnosis of decreased swallowing function is progressing steadily, and the Compnay hopes to begin the clinical performance test within three years.